الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 167 |  |  |
| | | from | 167 | | |
Abstract
Metabolic related fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, affects an estimated 25-30% of the global population. Because it is a multi-systemic illness, MAFLD may have catastrophic consequences. Hepatocellular carcinoma (HCC), cirrhosis, and liver failure are more common among alcoholics. Alcohol also raises the risk of cardiovascular disease, chronic renal disease, osteoporosis, cancer, and type 2 diabetes, among other problems.
A complex interplay between inherited susceptibility and environmental factors causes the disease’s convoluted progression, and there is some evidence that MAFLD and other metabolic disorders share certain genetic components.
The international community has now come to a new agreement on diagnostic criteria for MAFLD. Obesity, type 2 diabetes mellitus, or symptoms of metabolic dysregulation, in addition to hepatic steatosis, are necessary for the criteria to be met.
A worldwide health problem, chronic kidney disease (CKD) is linked to substantial morbidity, mortality, and healthcare expenses.
Metabolic associated fatty liver disease (MAFLD) patients were more likely to have more metabolic syndrome characteristics than our whole sample of chronic kidney disease (CKD) patients, including hypertension, diabetes, high cholesterol, and a high body mass index. This discovery lends credence to the idea that MAFLD is associated with the metabolic syndrome.
In the cross-sectional observational studies that provided the data, patients suffering from chronic kidney disease (CKD) were included. This research set out to compare the clinical presentation of healthy controls with that of individuals suffering from metabolically associated fatty liver disease (MAFLD). During the first twelve months of 2023, imaging and other non-invasive tests were employed to detect MAFLD.The research sample consisted of 108 people who visited the outpatient renal and urology clinic at Minia University Hospital. In addition, they conducted a comprehensive physical examination, took the patient’s medical history into account, ordered and reviewed a battery of tests from general and specialty laboratories, and completed radiographic examinations according to a precise procedure. To determine the extent of liver fibrosis, 2D shear wave elastography was employed.
This study aimed to evaluate the prevalence of metabolic associated fatty liver diseases (MAFLD) in individuals with chronic kidney disease (CKD) and identify potential risk factors for this condition.